The U.S. Centers for Disease Control and Prevention has flagged a sharp rise in extensively drug-resistant Shigella infections that resist every standard oral antibiotic doctors would normally reach for. About 5 percent of Shigella infections reported to the CDC in 2022 met the extensively drug-resistant, or XDR, definition, up from zero percent in 2015. With an estimated 450,000 shigellosis cases occurring in the United States each year and no FDA-approved oral treatment for XDR strains, the trend puts clinicians and patients in an increasingly difficult position.
Why XDR Shigella is outpacing available treatments
Shigella spreads easily through contaminated food, water, and direct person-to-person contact, causing bloody diarrhea, fever, and stomach cramps. Most cases resolve on their own, but severe infections require antibiotics. The problem is that XDR strains have developed resistance to azithromycin, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and ampicillin, which together represent the full menu of first- and second-line oral drugs. A CDC analysis covering 2011 through 2023 confirmed that no FDA-approved oral antimicrobial agents remain reliably effective against these strains. That leaves physicians reliant on intravenous options or off-label drugs, both of which drive up treatment costs and hospital stays and may be harder to access in outpatient settings.
The resistance is not static. Genes conferring drug resistance can move between bacteria on mobile genetic elements, meaning a Shigella strain that was treatable last month can acquire new resistance from neighboring gut bacteria. Genomic research published in Nature Communications traced how XDR Shigella sonnei lineages evolved and spread internationally through these mobile resistance elements, raising the question of whether the U.S. increase reflects repeated importations or domestic gene transfer within American transmission networks. Comparing plasmid backbones and single-nucleotide polymorphism distances in surveillance isolates collected before and after 2018 could help answer that question, but publicly available whole-genome sequence data with accession numbers remain limited, and many clinical laboratories do not yet perform routine whole-genome sequencing on Shigella isolates.
CDC surveillance data and the scale of resistant infections
The National Antimicrobial Resistance Monitoring System, or NARMS, has tracked a rising share of Shigella isolates resistant to both azithromycin and ciprofloxacin since 2017, according to updated clinical guidance for healthcare providers. An estimated 242,000 antimicrobial-resistant Shigella infections occur in the United States each year, and that figure includes strains with varying degrees of resistance, not only XDR. Still, the jump from zero percent XDR in 2015 to about 5 percent in 2022 signals that the most dangerous strains are gaining ground fast and that empiric oral therapy is increasingly likely to fail in high-risk patients.
Individual case reports add clinical texture to the surveillance numbers. A peer-reviewed report in the CDC journal Emerging Infectious Diseases documented a U.S. infection with XDR Shigella sonnei that met the agency’s XDR definition and illustrated the real-world difficulty of identifying and treating these infections in a hospital setting. In that case, the pathogen was resistant to all recommended oral agents, forcing clinicians to escalate to intravenous therapy and adjust treatment repeatedly as susceptibility results came back. Separately, another Emerging Infectious Diseases report described the detection of OXA-181 carbapenemase in Shigella flexneri, a resistance mechanism that could threaten even the intravenous carbapenem antibiotics sometimes used as a last resort. That finding, in an immunocompromised patient, signals that the resistance problem could extend beyond the current XDR definition if carbapenem-destroying enzymes become more common in Shigella.
The CDC has responded by issuing a Health Alert Network advisory that specifically warns clinicians and public health departments about the rise of XDR Shigella infections. The alert defines the resistance profile, outlines testing recommendations, and urges laboratories to perform antimicrobial susceptibility testing on all Shigella isolates rather than relying on standard empiric treatment. Antimicrobial-resistant Shigella infections have been rising since 2016, and the agency treats the XDR subset as an urgent concern because standard outpatient care simply does not work against these strains and because they can spread rapidly through households, childcare settings, homeless encampments, and sexual networks.
Clinical and public health challenges
For front-line clinicians, XDR Shigella complicates what used to be a relatively straightforward decision. When a patient presents with severe dysentery, providers historically prescribed an oral fluoroquinolone or azithromycin while awaiting stool culture results. Now, the CDC recommends that clinicians reserve antibiotics for patients with severe disease, those at risk for complications, or people who are likely to spread the infection to vulnerable contacts, and to base drug choices on susceptibility testing whenever possible. In communities where XDR cases have been documented, that means considering early infectious disease consultation and arranging access to intravenous therapy, even for patients who might otherwise have been managed at home.
Public health departments face a different set of pressures. XDR Shigella outbreaks require rapid case finding, contact tracing, and targeted hygiene interventions, but many jurisdictions lack the staffing to investigate every case in depth. Because Shigella can spread with very low infectious doses, standard advice about handwashing and safe food handling may not be enough in crowded shelters or sexual networks where fecal–oral exposure is more likely. Some health departments have responded by issuing alerts to clinicians serving men who have sex with men, people experiencing homelessness, and recent international travelers, emphasizing the need for stool testing and isolation precautions.
Infection control within healthcare facilities is another concern. Patients with XDR Shigella may shed the organism for weeks, and if they are not placed on appropriate contact precautions, the bacteria can spread to roommates, staff, or other vulnerable patients. Hospitals are being urged to reinforce basic enteric pathogen protocols-private rooms when available, dedicated bathroom facilities, meticulous environmental cleaning-and to ensure that staff understand that a history of recent diarrhea, even if resolved, can still signal ongoing shedding.
Gaps in genomic tracking and what to watch next
Several questions remain open. Public NARMS data do not yet include patient-level demographic breakdowns tied specifically to XDR isolates, which means researchers cannot easily map the outbreak by age, sex, travel history, or sexual network. State and local health department reporting on how many XDR cases are caught outside CDC reference laboratories is also incomplete, leaving the true case count uncertain and raising the possibility that XDR prevalence is already higher than reported. Clinical outcome records, such as hospitalization rates, duration of bacterial shedding after failed oral therapy, and rates of invasive complications, have not been published at scale for U.S. XDR Shigella cases.
The genomic picture is similarly incomplete. While international studies have mapped how XDR Shigella sonnei lineages spread across continents, detailed U.S. phylogenetic analyses comparing domestic and imported strains have not been released with enough granularity for independent verification. Without those data, it is difficult to determine whether the U.S. increase is driven mainly by repeated introductions from abroad, amplification within specific sexual or social networks, or horizontal gene transfer events that convert previously susceptible strains into XDR variants. Expanding whole-genome sequencing of Shigella isolates through public health laboratories and linking those sequences to de-identified clinical metadata would help clarify the transmission patterns and inform targeted interventions.
Looking ahead, experts are watching for several warning signs: evidence of sustained XDR transmission in childcare settings, increased detection of carbapenemase genes in Shigella, and reports of treatment failures even with intravenous regimens. At the same time, researchers are exploring nontraditional approaches such as bacteriophage therapy, microbiome-based strategies to reduce colonization, and vaccines that could protect high-risk groups. Until new tools arrive, however, the response will depend on meticulous hygiene, careful antibiotic stewardship, and stronger surveillance systems capable of catching XDR Shigella before it becomes entrenched in the broader community.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
